The work was led by Professor Michio Nakaya of the Research Institute of Environmental Medicine at Nagoya University, in collaboration with colleagues from Kyushu University and Tokushima University. Their central discovery concerns the metabolic machinery that scar-forming cells rely on to manufacture collagen, the structural protein that makes up roughly a fifth of the raw material in the form of a single amino acid: proline. By disrupting the supply chain for this building block, the team found they could throttle collagen production at its source.

Fibrosis is not unique to the heart. The same runaway deposition of collagen-based scar tissue can afflict the liver, where chronic injury can progress to cirrhosis, and it is estimated to contribute to as many as 45 percent of deaths in developed countries. Despite this enormous disease burden, no definitive therapy exists that directly suppresses the fibrotic process itself. Current treatments generally manage symptoms or slow progression rather than halting the underlying cellular program that turns healthy tissue into stiff, nonfunctional scar.

To understand why the heart is so vulnerable, it helps to look at the cells responsible. After inflammation or injury, specialized cells called myofibroblasts flood into the damaged area and begin producing collagen on an industrial scale, reinforcing the wound much as rebar reinforces concrete. In the short term this is protective, preventing the weakened heart wall from rupturing under pressure. But when the response becomes chronic, the accumulating collagen stiffens the myocardium, impairs contraction, and sets the stage for heart failure, which frequently develops in patients in the months and years following a myocardial infarction.

Because approximately 20 percent of collagen consists of proline, the Nagoya-led team reasoned that the way myofibroblasts produce and supply this amino acid might be a critical vulnerability. They began by comparing genes activated by physical stress with those switched on in mouse hearts after a heart attack, searching for molecular players common to both settings. This screen identified five overlapping candidates, among them Bcat1, the gene encoding branched-chain amino acid transaminase 1. The researchers homed in on BCAT1 because its role in myofibroblasts had never been explored, leaving open the possibility that it represented an untapped therapeutic target.

What they found was striking. In healthy mouse hearts, BCAT1 was barely detectable. But after a heart attack, levels of the enzyme rose sharply in collagen-producing cells, climbing in step with the progression of fibrosis. Follow-up experiments revealed that BCAT1 activates a cellular pathway that maintains the supply of proline, effectively functioning as part of the material-delivery system that fibrotic cells use to sustain their enormous output of collagen. In other words, the enzyme does not merely accompany scarring; it helps feed it.

The causal role of BCAT1 became clear when the team studied mice genetically engineered to lack the enzyme. After suffering a heart attack, these animals produced fewer proline-related enzymes and less collagen than their normal counterparts. They developed less scar tissue and, crucially, maintained better heart function than control mice. The histological evidence was equally compelling: heart tissue sections stained with Picrosirius red, which highlights collagen in red, showed markedly reduced collagen deposition in BCAT1-deficient mice 28 days after a heart attack compared with normal mice subjected to the same injury.

Genetic deletion, however, is not a practical treatment for patients who arrive at the hospital after an attack has already happened. So the researchers turned to pharmacology, testing a BCAT1 inhibitor called ERG240 in mice following induced heart attacks. The results were notable for their timing flexibility: ERG240 administration reduced scarring and preserved heart function even when treatment began seven days after injury, during the transition from the acute inflammatory phase to the chronic fibrotic phase. This delayed-treatment window matters enormously in clinical terms, because real-world interventions almost always occur after a heart attack rather than before it. A therapy that only works prophylactically would be of limited use; one that can reverse course after fibrosis has begun is far more valuable.

The mouse findings also appear to translate to human disease. When the team analyzed human heart tissue from patients with heart failure, they found elevated BCAT1 levels linked to increased fibrosis, suggesting that a similar enzyme-driven mechanism operates in human hearts. Intriguingly, the researchers also detected higher BCAT1 levels in the livers of patients with fatty liver disease, hinting that the same proline-supply pathway may drive fibrosis in organs well beyond the heart. The team’s next step is to determine whether the BCAT1-proline pathway also promotes fibrosis in the liver and other tissues, and to develop clinically applicable BCAT1-targeted therapies while assessing their safety, optimal dosing, and efficacy.

Perhaps the most attractive feature of BCAT1 as a drug target is its selectivity. Because the enzyme is mostly absent from healthy tissue and becomes primarily active in scar-forming cells, blocking it should, in principle, suppress pathological collagen production without disturbing the normal collagen turnover that healthy organs depend on. That specificity could translate into fewer side effects than existing anti-fibrotic treatments, which often act on broader pathways and carry a heavier burden of toxicity. As Nakaya put it, “We found that BCAT1 is a new driver of excessive collagen production in the fibrotic heart by increasing the supply of proline, a major building block of collagen. Importantly, pharmacological inhibition of BCAT1 suppressed cardiac fibrosis and preserved cardiac function, even when treatment started after fibrosis had begun to develop.” If the pathway holds up in further studies across organs and eventually in human trials, a metabolic vulnerability shared by fibrotic diseases of the heart, liver, and beyond may finally have a common weak point.

Subject of Research: The role of the enzyme BCAT1 in proline-dependent collagen production and cardiac fibrosis after heart attack

Article Title: Blocking enzyme reduces heart failure risk after heart attack in mice

Article References: Blocking enzyme reduces heart failure risk after heart attack in mice. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: BCAT1, cardiac fibrosis, heart attack, heart failure, collagen, proline, myofibroblasts, ERG240, Nagoya University, Journal of Clinical Investigation, enzyme inhibitor, fatty liver disease

The enzyme in question is succinate dehydrogenase, or SDH, a mitochondrial complex that sits at the junction of two of the cell’s most important energy systems: the tricarboxylic acid cycle and the electron transport chain. SDH has long been studied in the context of ischemia-reperfusion injury, where the drug malonate can reduce the damaging accumulation of succinate and limit mitochondrial reactive oxygen species during reperfusion. It has also drawn attention in cancer biology, because mutations in SDH genes drive dramatic metabolic reprogramming in certain tumors. The research team hypothesized that transiently inhibiting SDH after a myocardial infarction could push the adult heart back toward a more regenerative, fetal-like metabolic state.

Their earlier work had already shown promise: transient malonate treatment after infarction increased cardiomyocyte proliferation and angiogenesis, reduced fibrosis, and improved cardiac function in adult mice. Importantly, treatment delayed until seven days after injury still restored function, suggesting the effect was true regeneration rather than mere acute cardioprotection. What remained unclear was how this transient metabolic intervention rewired the heart at the level of genes and chromatin. To find out, the team deployed an unusually comprehensive toolkit: single-nucleus RNA sequencing, single-nucleus ATAC-seq to map chromatin accessibility, targeted metabolomics, and cell-type-specific genetic deletion of Sdhb, the gene encoding a core SDH subunit.

The multiomic analysis of mouse hearts treated with malonate for fourteen days after infarction revealed that nearly every major cardiac cell type, including cardiomyocytes, cardiac fibroblasts, endothelial cells, mural cells and myeloid cells, formed treatment-specific subclusters with distinct transcriptional and epigenetic profiles. In untreated infarcted hearts, profibrotic and extracellular matrix programs dominated, most strongly in fibroblasts. In malonate-treated hearts, the picture shifted toward metabolic, chromatin remodeling and proregenerative programs, particularly within cardiomyocytes. A specific cardiomyocyte subcluster emerging after treatment expressed genes associated with cell-cycle progression, cardiac development and neonatal-like regeneration, including Ccnd3, Lrrc10, Tcap, Cited2, Lifr and Ezh1, alongside activation of PI3K-AKT and AMPK signaling pathways known to support cardioprotective and proregenerative responses.

Chromatin analysis reinforced the story. The regenerative cardiomyocyte subcluster showed increased accessibility at the cell-cycle gene Ccnd3 and the metabolic regulator Pdk4, and enriched accessibility of motifs for the MEF2 family of transcription factors, which are central to cardiac development and regeneration, as well as FOXK1 and FOXK2, which promote cardiomyocyte proliferation. Fibroblasts told the complementary tale: in untreated infarcts, a subcluster expressed profibrotic genes such as Postn, Fn1, Runx1 and Acta2, marking activated myofibroblasts. After malonate treatment, that myofibroblast population shrank dramatically, and fibroblasts instead expressed reparative WNT/BMP signaling genes like Egr1 and Notch1 along with chromatin remodelers Kdm6b and Kdm7a, with chromatin accessibility mirroring the transcriptional shift.

The genetic models then dissected which cells matter most, and the results were strikingly asymmetric. Deleting Sdhb specifically in cardiomyocytes triggered a transient burst of proliferation, with roughly one hundred-fold more Ki67-positive cardiomyocytes and about threefold increases in mitotic and cytokinesis markers two weeks after induction. Yet this hyperplasia faded by four weeks, and although sustained deletion after infarction increased cumulative proliferation and reduced scar area, serial echocardiography showed progressive deterioration of systolic function rather than recovery. All cardiomyocyte-specific knockout mice eventually died by around eleven weeks after induction, whether or not they had suffered an infarction, underscoring that permanent SDH loss is ultimately harmful even as it briefly revives proliferation.

Metabolomics explained why the proliferative window is so narrow. Two weeks after Sdhb deletion, oxidative TCA cycle intermediates such as succinate, fumarate and malate were depleted, while reductive metabolism products like proline and ornithine accumulated, and amino acid pools were broadly remodeled with elevated 3-methylhistidine, a marker of myofibrillar protein breakdown. Electron microscopy revealed smaller, disorganized mitochondria with fewer cristae and disrupted sarcomeres, hallmarks of a less mature cellular state. Crucially, global levels of the histone marks H3K4me3 and H3K27me3, which mark active and repressive chromatin respectively, were reduced during the proliferative phase, directly linking mitochondrial metabolism to epigenetic state. In human induced pluripotent stem cell-derived cardiomyocytes, malonate, succinate and malate each boosted proliferation, while fumarate proved toxic, pinpointing specific TCA intermediates as candidate proproliferative signals.

Myofibroblast-specific Sdhb deletion produced an entirely different and arguably more therapeutically relevant outcome. When the researchers deleted Sdhb in activated fibroblasts using a Postn-MerCreMer system, the animals showed robust suppression of myofibroblast activation, with reduced POSTN, COL3A1 and alpha-SMA staining at one and two weeks after infarction, smaller scars, and significantly improved ejection fraction and fractional shortening as early as one week after injury, sustained through four weeks. Notably, this functional benefit occurred without any increase in cardiomyocyte proliferation, and surviving myocardial area was unchanged early on, indicating the improvement stemmed from restraining fibrotic remodeling rather than protecting muscle. In cultured neonatal cardiac fibroblasts, malonate suppressed TGF-beta1-induced activation, proliferation and migration while reducing H3K4me3 and COL3A1 protein, suggesting SDH inhibition silences profibrotic genes through epigenetic repression.

CUT&RUN profiling of purified cardiomyocytes and fibroblasts tied the whole mechanism together. In malonate-treated infarcted hearts, differentially expressed genes showed increased H3K4me3 and decreased H3K27me3 relative to matched background genes, and thousands of histone-mark-associated loci differed between treatment groups. H3K4me3 sites enriched after malonate mapped to genes such as Lrrc10, Lifr, Pdk4 and Tecrl and to pathways governing cardiac muscle development and contractile function, while reduced H3K27me3 mapped to cardiac morphogenesis and tissue remodeling programs. The authors propose a biphasic model: transient suppression of oxidative metabolism permits cardiomyocyte cell-cycle reentry and chromatin remodeling toward a neonatal-like state, and subsequent restoration of SDH activity allows redifferentiation and maturation. Permanent genetic deletion, by contrast, blocks that recovery phase and may even constrain pyrimidine biosynthesis through succinate-mediated effects on aspartate metabolism, imposing replication stress that transient pharmacology avoids.

The broader lesson is that heart regeneration is not a single-cell phenomenon. Cardiomyocyte proliferation alone, as the knockout experiments demonstrate, cannot restore function; the antifibrotic reprogramming of fibroblasts is equally essential, and the two effects must be coordinated in time. Transient, reversible, multicellular SDH inhibition achieves what permanent genetic deletion in any one cell type cannot. The work also leaves open questions, including the roles of endothelial, mural and myeloid cells, the earliest temporal events after injury, and the long-term safety of metabolic intervention with respect to cardiomyocyte maturation and arrhythmogenic risk. Still, by identifying SDH as a metabolic-epigenetic hub linking mitochondrial function to chromatin state across the injured heart, the study establishes metabolic-epigenetic crosstalk as a credible therapeutic axis for coaxing the adult myocardium back into a developmental program it abandoned long ago.

Subject of Research: Metabolic and epigenetic mechanisms of cardiac regeneration following succinate dehydrogenase inhibition after myocardial infarction

Article Title: A metabolic–epigenetic switch governs multicellular cardiac repair following succinate dehydrogenase inhibition

Article References: Fan, Y., Nuttall, D. J., Zhao, Y., Abbasian, D., Shoffler, C., Petucci, C., Paltzer, W. G., Chang, Y.-L., Marchant, J., Presas-Ramos, D., Atlass, K. P., Nemr, S. A., Bae, J., Ranade, S. S., Colas, A. R., Li, X., Martin, J. F., & Mahmoud, A. I. (2026). A metabolic–epigenetic switch governs multicellular cardiac repair following succinate dehydrogenase inhibition. Nature Cardiovascular Research. https://doi.org/10.1038/s44161-026-00881-9

Image Credits: AI Generated

DOI: 10.1038/s44161-026-00881-9

Keywords: cardiac regeneration, succinate dehydrogenase, malonate, myocardial infarction, cardiomyocyte proliferation, fibrosis, epigenetics, H3K4me3, H3K27me3, metabolism, single-nucleus sequencing, myofibroblasts

The core problem the researchers set out to solve is one that plagues much of modern pharmacology: getting enough drug to the diseased tissue without poisoning the rest of the body. Pirfenidone is one of only two antifibrotic agents approved for pulmonary fibrosis, yet its clinical benefit is limited by poor accumulation at the sites of active scarring and by systemic side effects that arise when the drug circulates throughout the body after oral or intravenous administration. Patients may tolerate the treatment poorly, and the lesions themselves receive only a fraction of the administered dose.

The team’s solution combines two ideas that have each attracted intense interest in recent years. The first is the exosome, a nanoscale vesicle naturally released by cells to shuttle proteins, lipids, and genetic material between them. Because exosomes are biological in origin, they are relatively invisible to the immune system and can cross biological barriers that defeat synthetic nanoparticles. The researchers harvested exosomes from 293T cells, a standard laboratory cell line, and verified their identity and quality using transmission electron microscopy to visualize their cup-shaped morphology, nanoparticle tracking analysis to measure their size distribution and concentration, Western blotting to confirm the presence of characteristic exosomal marker proteins, and high-performance liquid chromatography to quantify how much pirfenidone each vesicle had been loaded with.

The second idea is molecular targeting. Fibrotic lung tissue is distinguished by the activity of fibroblast activation protein, or FAP, a molecule displayed on the surface of the activated fibroblasts that drive scarring but largely absent from healthy tissue. Using copper-free click chemistry, a bioorthogonal reaction that joins molecules together efficiently under gentle physiological conditions, the team decorated the surface of the exosomes with anti-FAP antibodies. The result is a drug-loaded vesicle that behaves like a guided missile: once in the bloodstream or the airways, it seeks out cells bearing FAP and docks onto them, concentrating its therapeutic payload precisely where the fibrotic process is most active.

How the payload gets to the lung proved to be just as important as the vesicle carrying it. The researchers compared two routes of administration in a bleomycin-induced mouse model of pulmonary fibrosis, a widely used experimental system in which a single dose of the chemotherapy drug bleomycin triggers progressive lung scarring that mimics the human disease. One group of mice received the engineered exosomes by tail vein injection, the standard route for systemic drug delivery. Another group inhaled the same vesicles as an aerosol generated by a nebulizer, a device that converts liquid formulations into fine droplets that can be breathed deep into the lungs.

The difference was striking. In vivo fluorescence imaging, which tracks where labeled vesicles travel in a living animal, showed that nebulization dramatically enhanced both the accumulation of the engineered exosomes in the lungs and the length of time they remained there, compared with systemic injection. Confocal microscopy of lung tissue sections confirmed the same pattern at the cellular level. When the researchers assessed therapeutic outcomes, the nebulized formulation produced better lung histopathology, meaning less architectural distortion of the tissue, and reduced collagen deposition, the hallmark protein accumulation that stiffens fibrotic lungs. The inhaled route also produced stronger suppression of the TGF-β1/p-Smad3 signaling axis, a central molecular pathway through which the cytokine TGF-β1 drives fibroblasts to become collagen-secreting myofibroblasts. Because this pathway sits at the heart of the fibrotic cascade, its more complete inhibition is a meaningful mechanistic win.

But the study went beyond drug delivery and probed how the treatment reshapes the fibrotic microenvironment itself. Using single-cell RNA sequencing, a technique that profiles gene expression in individual cells within a tissue, the researchers found that nebulized delivery of the engineered exosomes attenuated the activation of fibroblasts and myofibroblasts, the cellular engines of scarring. At the same time, the treatment promoted polarization of immune cells toward a repair-associated state, shifting the balance of the lung’s cellular ecosystem from one that perpetuates injury toward one that promotes healing. Proteomic analysis of the tissue, combined with immunofluorescence staining to localize specific proteins, identified AXL, a receptor tyrosine kinase, as a candidate regulatory molecule associated with these beneficial effects.

To test whether AXL was genuinely involved rather than merely correlated, the team turned to cell-based functional experiments. In MLE12 cells, a mouse lung epithelial cell line, and in bone marrow-derived macrophages driven to polarize toward pro-fibrotic phenotypes, the researchers demonstrated that modulating AXL influenced the cellular behaviors that fuel fibrosis. Manipulating the receptor affected pro-fibrotic cellular functions, altered TGF-β1/p-Smad3 signaling, and changed the levels of oxidative stress, a form of cellular damage that both accompanies and promotes fibrotic remodeling. These findings position AXL-associated signaling as a potential mechanistic node in the fibrotic microenvironment and, intriguingly, as a therapeutic target in its own right, suggesting that the exosome platform may work partly by engaging endogenous repair pathways rather than simply delivering a passive drug cargo.

The implications of the study extend in several directions at once. Clinically, an inhaled, targeted formulation of pirfenidone could allow lower doses to achieve greater effect at the lesion while sparing patients the systemic exposure responsible for many side effects, a meaningful prospect for a disease whose treatments are often poorly tolerated. Technologically, the work demonstrates a practical pipeline for engineering exosomes with disease-specific ligands via click chemistry, loading them with small-molecule drugs, and administering them noninvasively through the airways. Scientifically, the identification of AXL as a regulator of the fibrotic microenvironment adds a new thread to the growing understanding of pulmonary fibrosis as a disease of cellular ecology rather than simple scar accumulation. The authors note that their findings establish nebulized anti-FAP-engineered exosomes as a promising targeted delivery platform and highlight microenvironment-focused intervention as a strategy worth pursuing. As with any preclinical mouse study, translation to human patients will require further validation, dose optimization, and safety testing, but the combination of a proven drug, a homing mechanism aimed at a validated disease marker, and a patient-friendly inhalation route gives this platform an unusually clear path toward clinical evaluation.

Subject of Research: Targeted nebulized exosome delivery of pirfenidone for pulmonary fibrosis therapy

Article Title: Mechanisms of nebulized anti-FAP-engineered exosomes encapsulating pirfenidone for targeted therapy of pulmonary fibrosis

Article References: Chen, H., Zhang, G., Kang, C., Liu, H., Tian, W., & Peng, P. (2026). Mechanisms of nebulized anti-FAP-engineered exosomes encapsulating pirfenidone for targeted therapy of pulmonary fibrosis. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08894-5

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08894-5

Keywords: pulmonary fibrosis, exosomes, pirfenidone, nebulization, drug delivery, fibroblast activation protein, TGF-beta signaling, AXL, single-cell RNA sequencing, myofibroblasts, targeted therapy, nanomedicine

The stroma, the connective tissue framework that surrounds and supports the milk-producing ducts and lobules of the breast, has increasingly moved from the periphery of cancer research to its center. Far from being a passive scaffold, stromal cells communicate actively with epithelial cells, secreting growth factors, remodeling the extracellular matrix, and modulating inflammation. In cancers, this crosstalk can either restrain tumor growth or fuel it. The new research asked a deceptively simple question: if reproductive events alter breast cancer risk, do they also leave detectable fingerprints in the stroma of healthy, benign tissue?

To answer it, the investigators turned to benign breast biopsy samples, a resource that captures tissue at an intermediate point—neither fully normal nor malignant. Benign breast disease itself is a well-established risk marker for subsequent breast cancer, and the composition of benign biopsies, including features such as usual ductal hyperplasia, cysts, and stromal fibrosis, has been linked to long-term risk. By examining stromal marker expression in these samples, the team sought to connect the epidemiology of reproductive factors with the microscopic biology of the tissue.

The study focused on markers that characterize distinct stromal states. Among the most important were proteins associated with fibroblast activation and extracellular matrix remodeling, including markers of myofibroblasts—the contractile, matrix-producing cells that become prominent during wound healing and are often abundant in the tissue surrounding tumors. The researchers also assessed markers reflecting the density and organization of collagen and other matrix components. Using immunohistochemical staining and quantitative pathology methods, they scored the expression of these markers across biopsy samples and then tested whether the scores varied systematically with each donor’s reproductive history.

The results revealed clear associations. Women who had never given birth showed stromal marker profiles that differed from those of parous women, consistent with the long-standing epidemiological observation that nulliparity increases breast cancer risk. Among women who had borne children, the timing of the first pregnancy emerged as a significant variable: earlier age at first full-term pregnancy was linked to stromal features associated with a more differentiated, mature tissue state, while later first pregnancies were associated with profiles suggestive of incomplete stromal maturation. This mirrors the well-documented protective effect of early pregnancy, which is thought to drive the breast epithelium and its supporting tissue through a final differentiation program that reduces susceptibility to malignant transformation.

Breastfeeding also left its signature. Women with a history of lactation showed distinct stromal expression patterns compared with those who had never breastfed, a finding that aligns with epidemiological evidence that cumulative breastfeeding duration lowers breast cancer risk. The involution process that follows pregnancy and lactation—during which milk-producing structures are pruned back and the tissue remodels—involves waves of matrix breakdown and repair. The new data suggest that the stroma participates in this remodeling in ways that vary with lactation history and that these variations persist in tissue sampled years later, during routine clinical biopsies.

Number of births added further nuance. Multiparity, which epidemiological studies associate with a transient increase in risk shortly after pregnancy followed by long-term protection, was reflected in stromal marker expression patterns that differed from those of women with fewer births. The authors interpret these patterns as evidence that the stroma undergoes cumulative, history-dependent remodeling with each reproductive cycle. Rather than resetting completely after each pregnancy, the breast’s connective tissue framework appears to accumulate changes that integrate the number, timing, and character of reproductive events into a durable tissue phenotype.

The technical implications of the study extend beyond reproductive epidemiology. If stromal markers in benign biopsies encode risk-relevant biology, they could eventually serve as tissue-based biomarkers that sharpen risk assessment beyond what clinical and family history alone can provide. Current models of breast cancer risk—used to determine screening intensity and prevention strategies—rely heavily on demographic factors, reproductive history, mammographic density, and genetic variants. Incorporating quantitative stromal features from benign biopsies, which are already obtained and archived in routine clinical practice, could add a layer of biological information that is directly grounded in the microenvironment where cancers arise. The researchers caution that their findings establish associations, not causal mechanisms, and that validation in independent cohorts will be essential before any clinical application.

The study also speaks to a broader conceptual shift in cancer biology: the recognition that cancer risk is inscribed not only in the genome of epithelial cells but in the state of the tissue as a whole. The stroma of the breast changes dramatically across the reproductive lifespan—at puberty, with each menstrual cycle, during pregnancy and lactation, and at menopause—and each transition involves coordinated changes in fibroblast behavior, immune cell infiltration, matrix composition, and mechanical properties. The new findings suggest that these transitions are not fully reversible, and that the stroma retains a memory of reproductive events. Understanding how that memory is encoded—whether through epigenetic modifications in fibroblasts, persistent alterations in matrix cross-linking, or long-lived changes in stromal cell populations—is now a central question for follow-up research.

For the millions of women who undergo benign breast biopsies each year, the study offers a glimpse of a future in which the tissue removed during a routine procedure yields far more information than a simple benign diagnosis. By reading the stromal record of reproductive history alongside conventional pathological features, clinicians may one day better distinguish which benign lesions carry meaningful future risk. In the nearer term, the work provides a mechanistic bridge between decades of epidemiological observations about pregnancy, breastfeeding, and breast cancer, and the microscopic biology of the tissue microenvironment—demonstrating that the protective and risk-modifying effects of reproduction are, quite literally, woven into the fabric of the breast.

Subject of Research: Association between reproductive factors and stromal marker expression in benign breast biopsy samples

Article Title: Reproductive factors and the expression of stromal markers in benign breast biopsy samples

Article References: Ratcliffe, M., Heng, Y. J., Guzman-Arocho, Y. D., Rosner, B., Tamimi, R. M., & Yaghjyan, L. (2026). Reproductive factors and the expression of stromal markers in benign breast biopsy samples. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03615-7

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03615-7

Keywords: breast stroma, benign breast biopsy, reproductive factors, parity, breastfeeding, stromal markers, breast cancer risk, extracellular matrix, myofibroblasts, tissue microenvironment, age at first pregnancy, tissue remodeling